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Abstract 
Background: Strategies to decrease the burden of cervical cancer in developed 
countries are often difficult to implement in low resource settings, which has 
stimulated researchers and others to search for novel approaches for screening. 
Colposcopy offers some advantages that might make it a reasonable strategy as a 
standalone screen and treat protocol in communities where the incidence of 
disease is high. To date, results for the screening accuracy of colposcopy as a 
screening tool have varied widely from low to high sensitivity and specificity in 
different studies. 
Methods: In this study, I analyzed cross sectional data from the medical records of 
2,094 self referred women in a community cervical screening program in Haiti. 
The patients included in the final analyses received some combination of Pap 
smear, colposcopy and/or cervical biopsy, which allowed me to compare these 
techniques. The final study populations included 198 women who had both Pap 
smear and cervical biopsy, and 221 patients who had both colposcopy and 
cervical biopsy. The main outcome measure (cancer and precancer diagnoses) 
were operationalized as mild dysplasia or worse lesions on cervical biopsy. 
Diagnostic accuracy was determined by calculating the sensitivity, specificity, 
positive predictive values, and negative predictive values with 95% confidence 
intervals using cervical biopsy as the gold standard. 
Results: The prevalence of dysplasia or cancer on biopsy for the study 
populations was 41.9%-48.0%% while prevalence detected by Pap was 30.8%. 
Prevalence in the study populations detected by colposcopy was 66.7%-70.1%. 
Pap smear had a sensitivity of 68.7% (CI 57.6-78.4) and specificity was 96.5% 
(CI 91.0-99.0) using biopsy as the gold standard. The sensitivity for colposcopy 
was 96.2% (CI 91.0-99.0) compared to biopsy, and a specificity of Sp 53.9% (CI 
44.0-63.0). 
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Conclusion: Colposcopy identifies a population that includes most ofthe 
dysplasia at a price of including many false positives, placing the screened 
population at a significant risk of over treatment. Therefore, colposcopy is a 
reasonable screening strategy if the disease prevalence is high in the population of 
interest and the co-morbidity from over treatment is low. 
Introduction 
Cervical cancer disproportionately affects resource-poor nations, where 85% of 
deaths from cervical cancer and 80% of new cases arise annually 14. Haiti shares 
a heavy amount of this burden. For example one study estimated an age-
standardized mortality rate (ASR) of 53.5 per 100,000 person years (p-y) in 
20005• This contrasts starkly with rates in a mid-income country such as 
Argentina, in which the same study estimated the mortality rate at 7.3 ASR per 
100,000 p-r. The need for adequate prevention services is substantial and 
effective prevention efforts in low resource nations have been analyzed in many 
studies 1• 3• 6·9• One strategy that has been developed from this research, the see 
and treat method, has demonstrated the ability to decrease prevalence of precursor 
cancer lesions using HPV DNA testing or Visual Inspection with Acetic Acid. 
Colposcopy has characteristics that make it suitable for use in a screen and treat 
protocol; however diagnostic accuracy has varied widely between studies. 
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Barriers in access to health services in these nations, and especially Haiti, create 
special challenges in the development of screening programs. Factors including 
high rates of loss to follow-up, lack of transportation and finances for treatment, 
lack of existing health systems to address the issues, lack of knowledge, and 
cultural traits that hinder women from obtaining cervical screening have impeded 
efforts in many countries 3· 7• 10• Because of these difficulties, women that access 
care often do so because symptoms have impeded with their daily livelihood 
and/or they have an advanced and untreatable stage of cervical cancer with a 
tertiary care that is severely limited or non-existant1· 3· 7• 11· 12. The interaction of 
these factors fuels the need for novel screening and treatment protocols. One-day 
screen and treat protocols have been instituted in the past decade in many low 
resource nations in order to curb high incidence and mortality from cervical 
cancer9,13·15. 
Colposcopy as a Screening Method 
The best screening method for cervical cancer is one that can reduce the burden of 
disease while also proving to be inexpensive and reproducible, independent of 
pathology services, minimizing over treatment, side effects or complications, and 
socio-culturally acceptable16. Because of the interplay of political and economic 
factors at the macro level in Haiti, this nation's medical systems and public health 
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infrastructures have been severely weakened17• 18• As such, prior to this initiative, 
services for cervical cancer screening were nonexistent. For the past 13 years, 
Family Health Ministries, Inc. (FHM), a US based 50lc3 nonprofit organization, 
has supported efforts to develop a cost-effective cervical cancer prevention 
program in Leogane, Haiti. This study is FHM' s first evaluation of the efficacy of 
this screening method, yet patient acceptability and cost effectiveness remain to 
be determined. 
The screening and treatment protocol initially instituted thirteen years ago 
involved conventional methods used in the US and Europe, yet issues have arisen 
hindering effective screening. For example, physicians asked their patients to 
return for Pap smears, colposcopy, and biopsy results or evaluations, but follow 
up rates were very low. Furthermore, many Pap smear results could not be 
determined because inflammation on the slides obscured the sample. With 
assistance from FHM, they incorporated a new protocol for screening women into 
the typical screening strategy used in the United States. It involves making 
blinded preliminary diagnoses of the cervix using colposcopy, which has the 
potential for use in a one day screen and treat protocol. This method does not 
stray from US standard of care and allows for a comparison between colposcopy 
diagnoses and the gold standard diagnoses with biopsy. As a screening method, 
colposcopy involves the application of acetic acid to the cervix followed by visual 
inspection with the colposcope for dysplastic lesions. The physician's diagnostic 
impression was recorded. If colposcopy demonstrates good accuracy, 
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cryotherapy could be performed to remove lesions on the same visit. This is called 
a "see and treat" method and is different from diagnostic colposcopy, the 
conventional use for colposcopy. Traditionally, a colposcopy procedure requires 
a biopsy when abnormalities are detected. The see and treat method does not 
require biopsy before treatment, and if accurate, pathology services would not be 
necessary. 
Using colposcopy as a first line screening method is unique and currently 
published data addressing its efficacy in low resource settings is limited. 
Traditionally, colposcopy has only been used as a diagnostic tool in developing 
nations. It requires a skilled professional and the cost and maintenance of a 
colposcope may be prohibitive. Yet, once these resources have been acquired, as 
in the case of this Haitian program, it may prove to be more cost effective while 
also serving the main goal of decreasing cervical cancer mortality19• 
Purpose of the Study 
The purpose of this study is to perform a diagnostic accuracy analysis of the see 
and treat colposcopy method and Pap smear analysis by determining the 
sensitivity and specificity of each test compared to biopsy results as recorded in 
the Leogane screening program. Few published studies describe the use of 
colposcopy as a screening method, or its use in a see and treat protocol. The 
screening colposcopy procedures used in Haiti might be performed effectively in 
situations where there is a high risk of loss to follow up in the patient population, 
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while still adequately screening for cervical cancer. Because of the unknown 
efficacy of this method, traditional colposcopy was also performed on each 
patient with biopsy when dysplastic-appearing lesions were present. If these 
lesions were present near the endocervical canal, endocervical curettage and/or 
biopsy of the ectocervix was performed. A Pap smear interpreted by adequate 
cytology services has been performed on nearly all colposcopy patients in order to 
ensure accuracy and precision of colposcopy. 
In this study, I will compare the effectiveness of Pap smears and screening 
colposcopy as primary screening methods to identifY cervical dysplasia in a 
population subject to poor access to resources. The colposcope may be ideal for 
use as a screening tool in Leogane because 
1. It is more sensitive than Pap smears for identifYing dysplasia20 
2. It is less dependent on pathology services at a site that has acquired 
equipment and a skilled physician 
3. It is less expensive than Pap smear after the skills and equipment have 
been acquired 
4. It decreases the number of visits that women have to make to complete 
their diagnosis and therapy19 
Literature Review 
Many public health systems and/or advocacy organizations worldwide have 
evaluated the use of see and treat methods in low resource settings in order to 
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determine their efficacy compared to multiple visit screening, diagnostic and 
treatment methods. A summary of the results for all methods is provided in Table 
1. This section reviews currently used methods in order to identify factors that 
may lead to the success or failure of a novel colposcopy screen and treat method. 
Conventional Cervical Cytology 
Conventional cervical cytology with collection and examination of cervical 
cytology has been the most widely implemented strategy worldwide, yet it 
requires a health professional to collect the sample, cytotechnicians to process, 
stain and read smears, and a cytopathologist to do final reporting16• Reliable 
testing depends on the presence of a quality controlled laboratory and personnel, a 
method to relay results to patients, and usually a time lag between sample 
collection, diagnosis, and reporting16• Additionally, cytology does not identify the 
site of the lesion. The sensitivity and specificity of cytology in developing 
nations varies widely because of differences in quality of services. For instance, 
in Zimbabwe, Pap smear sensitivity for mild dysplasia or worse lesions was 
29.6% (95% CI 25.6%-33.8%), but was higher at 78.3% inS. Africa21•22• 
Hutchinson et al's study in Costa Rica demonstrated a sensitivity for High Grade 
Squamous Intraepithelial Neoplasia of77.8% (p<0.001)23• Specificity for Pap 
smear in Zimbabwe was 92.3% (90.9-93.6) but was higher at 96.5% in South 
Africa. While conventional cytology screening has been shown to reduce 
cervical cancer mortality in developed nations, data from randomized controlled 
trials in developing nations are lacking24. 
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Liquid Based Cytology 
Liquid based cytology (LBC) is another method of cervical cancer screening and 
uses fluid preservative to maintain cell features. Advantages to this method 
include improved transfer of cells to slides and readability because it is associated 
with fewer problems such as air-drying artifact, blood and inflammatory 
fragments, uneven layering of cells24• One study done in Costa Rica found that 
LBC had a higher sensitivity than conventional cytology, yet data supporting 
there is no proof that this method is efficacious in reducing cervical cancer in a 
low income nation23• 25. Furthermore the cost of LBC is greater than conventional 
cytology, requires specific equipment and can thus be prohibitive to programs in 
developing nations19•24• Testing for HPV DNA in developing nations encounters 
similar problems to those ofLBC in terms of requiring health system 
infrastructure for sample analyses. The benefit to this method has been its fair to 
excellent level of sensitivity worldwide in detecting CIN 2-3 and invasive cancers 
at 61-100% and specificity of61 %-91% as highlighted in Franco et al's 
systematic review5• 
Visual Inspection with Acetic Acid 
One inexpensive method that has been implemented in many low resource nations 
because of the low level of trairling required is visual inspection with acetic acid 
(VIA). Performing the test involves application of3-5% acetic acid to the cervix 
followed by examination of the cervix by the physician for acetowhite areas near 
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the transition zone. The transition zone is a circular area of the cervix where 
columnar cells of the endocervical canal meet with squamous cells of the external 
cervix. This site is important because cervical cancers are believed to originate at 
this site. While this method is not specific for cervical dysplasia, neoplastic areas 
appear more dense and whitened near the transition zone or close to the external 
os24• Most commonly, results are classified as negative or positive as uniform 
criteria for reporting have not yet been established internationallj4• Because 
treatment such as cryotherapy may be performed in the same visit, this method 
bypasses complicated logistics required in diagnosis and treatment by other 
methods. 
International studies have shown that the sensitivity of VIA measured in cross 
sectional studies ranged from 67-79% and specificity from 49-86% when 
performed in nations such as India, South Africa, Zimbabwe, and China24• 26. 
Another large good quality clustered randomized controlled trial (n= 142,701) 
done in India showed that VIA was significantly better than HPV testing and 
cytology in identifying condyloma and CINl (p<O.OOI) and there was not a 
significant difference in test ability to differentiate between CIN2 or 3 27. 
Because of the low specificity and fair sensitivity reported in most studies, this 
screening method lends itself to an increased risk for over-treatment. 
Recent research has supported the use of VIA as a tool to reduce the incidence of 
cervical dysplasia in a screen and treat protocol in a South African randomized 
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controlled trial comparing efficacy of VIA and HPV DNA testing in relation to 
efficacy of screen and treat methods9• Denny eta! (2005) published a good 
quality study measuring the efficacy of the visual inspection with acetic acid 
(VIA) method versus HPV DNA testing in the South African township of 
Khayelitsha. This randomized control trial screened 6,555 non-pregnant women 
age 35-65 with VIA and HPV DNA testing after which they were randomized to 
one of three groups: In one group, those patients who were HPV positive were 
treated with cryotherapy; In a second group, all patients with positive VIA results 
were treated; In the third group all patients were subject to further evaluation and 
treatment until six months later. At the six month endpoint, colposcopy was 
performed on all women by a blinded physician. This physician also performed 
an endocervical curettage on all women and biopsied all acetowhite lesions. After 
twelve months all women who had positive HPV or VIA results and a subset of 
negative tests received repeat colposcopy at twelve months. 
The results at six months demonstrated that 0.80% of the HPV DNA group had 
CIN 2 (95% CI 0.4%-1.2%) and2.23%ofthe VIA group had CIN 2 (95% CI 
1.57%-2.89%). For the delayed evaluation group 3.55% had CIN 2 (95% CI 
2. 71 %-4.39%). These results were significant as p<O.OOI for the HPV DNA 
group and p=0.02 for the VIA groups. Similar results were found at twelve 
months where the HPV group had the largest reduction followed by the VIA 
method and the delayed group had a 5.41% detection prevalence. Overall this 
study demonstrated that the HPV DNA method was slightly better than the VIA 
method in preventing the development of increased dysplasia, yet both methods 
were efficacious in reducing cervical dysplasia and inhibiting the progression to 
cervical cancer. 
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In the Denny et ai study, the patients were randomized by a computer generated 
schedule and patients, health care providers (except for nurses performing 
cryotherapy treatment) and patients were blinded to treatment strategies. In 
addition, allocation concealment of the groups hid diagnostic and treatment from 
the researchers. It was not clear how recruitment of this population took place 
other than the fact that they came from the township ofKhayelitsha. While 
systematic measurement bias in colposcopic evaluation may have occurred, this 
issue is inherent in this diagnostic procedure and inter-observer discrepancy may 
have led to variable results28• Furthermore, the size of the study population lends 
itself to decreased random error. The study is generalizable to women age 35-65 
in other developing nations as the study population was large and gave statistical 
power to the analysis. Of note, the township of Khayelitsha is comprised of 90% 
black African women and 10% "colored" women thus this study is applicable to 
similar populations7• 
Cost-effectiveness for Other Methods 
Cost effective analyses comparing VIA method to cytology and HPV testing have 
been done to evaluate the role this method may play in developing nations. 
Goldie et a!' s estimated cost effectiveness by using a computer generated model 
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based on a 30 year old black South African woman's risk, incidence, natural 
history and mortality of cervical cancer. They compared three screening methods 
in low resource settings and found that HPV testing was usually more effective 
with a 27% cancer incidence reduction, but was more costly ($39/year of life 
savedi9• In addition, HPV testing required two visits for screening and treatment. 
Visual inspection methods were slightly less effective (26% cancer incidence 
reduction) yet only required one visit and were not only cost effective but cost 
saving29• Finally cytology was less effective than VIA or HPV testing in low 
resource settings with a 19% incidence reduction and highest cost a $81/YLS 29. 
Overall, VIA and HPV testing were the best methods for screening according to 
that analysis. Mandelblatt et al' s cost effective analysis was based on a 
simulation model of a Thai population and evaluated seven screening methods 
including VIA, HPV testing, and combinations of same day, multiple day 
screening and treatment approaches. Their study revealed that VIA in a screen 
and treat program performed at 5 year intervals in ages 35-55 was the least 
expensive and saved the most lives and had while HPV screening cost slightly 
more
30
• Cost effectiveness studies and efficacy for LBC in reducing the burden of 
suffering in developing nations remains to be established. 
Overall Efficacy of Screen and Treat Methods 
Screen and treat methods have thus been demonstrated to be efficacious and cost-
effective. Furthermore, patients found at least one method acceptable in a study 
performed in Thailand in which 98.5% of the study population with abnormal 
VIA exam accepted immediate treatment within the same visit (n=798)31 • This 
study reported no complications and a 4.4% return rate of treated women for a 
perceived problem secondary to treatment31• Many of these studies have used 
colposcopy and colposcopy-directed biopsy as a diagnostic adjunct to verify the 
efficacy of these methods, yet few studies have evaluated colposcopy as a 
screening tool in a see and treat approach. This method is currently used in 
clinical practice in addition to a conventional screening strategy with Pap smear 
and biopsy in Leogane, Haiti. 
Colposcopy as a primary screening method 
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Colposcopy was initiated into US practice in the 1970's as a diagnostic procedure 
for women who had abnormal Pap smears, cervical, vaginal or vulvar lesions and 
colposcopic-guided biopsy remains the gold standard for cervical diagnosis in 
high income nations32• It is not often used in low-resource settings because it 
requires a skilled technician, and the cost of equipment can be prohibitive to 
prevention programs in resource poor nations9• Colposcopic evaluation is also 
similar to other visnal screening or diagnostic methods in that it can be subjective 
based on the observer and their skilllevel28• Yet its use as a screening method 
may be adequate for use in Cervical Cancer Prevention Program for several 
reasons. Local Haitian physicians have complained that Pap smears have not 
been sufficient to screen the local population as many Pap results have obscuring 
inflammation, and may mask accurate pathological diagnosis. In a community 
whose patients have high risk for loss to follow-up and that has also acquired a 
facility, equipment and trained staff to carry out this method, it may provide a 
satisfactory method for screening and prevention as it allows for same day care. 
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Mitchell et al performed a meta-analysis in order to characterize colposcopy in the 
diagnosis of squamous intraepitheliallesions in patients that had abnormal Pap 
smears. This was done in light of the development of new technologies currently 
researched in developed nations, such as speculoscopy and fluoroscopy, but have 
not been implemented in underdeveloped nations at this time33• They pooled data 
from nine studies and noted that in the US and Europe, the study with the lowest 
sensitivity was 87.0% ( +-5%) while the study with the highest sensitivity had 
results of99% (+-6%). The lowest specificity was 23% (+-6%) and the highest 
was 87% (+-1%)20. Mitchell et al found that the specificity increased slightly 
when only distinguishing between high grade dysplasia and cancer from lower 
grade lesions20• Because of high sensitivity and low specificity of colposcopy in a 
screen and treat protocol for all cervical lesions, this method lends itself to a risk 
of over treating patients. Because this meta-analysis demonstrated that the 
weighted average for sensitivity was higher than that for VIA, and specificity was 
higher than most results for VIA, colposcopy is generally a more accurate method 
for screening. This suggests that this tool is better suited for a population with 
higher prevalence of more advanced lesions. 
Schneider et al performed a study with 5,455 women in Germany comparing 
screening methods for high grade dysplasia (CIN2/3) and cancer including Pap 
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smear, HPV DNA testing, and screening colposcopy using biopsy as the gold 
standard diagnostic tool34• They found that the corrected sensitivity for 
colposcopy with 95% confidence intervals was 13.3 (7.0-20.5) and specificity was 
99.3 (99.0-99.6). The positive predictive value (PPV) for colposcopy was 38.1 
(21.3-58.3) and the negative predictive value (NPV) was 97.3 (96.7-97.8). The 
sensitivity for cytology was slightly higher at 20.0 (10.8-28.6) and specificity was 
99.2% (98.8-99.5). Cytology had a PPV of70.6 (41.1-95.3) and an NPV of97.5 
(96.9-98.0). Overall, traditional cytology was able to identify patients with 
disease better than screening colposcopy, although the ability to identifY patients 
that were negative for ClN II or ill was very close. Screening colposcopy had a 
higher PPV than cytology, however, and the NPV for each was similar. This 
study was of fair to good quality as patients were not randomized and therefore 
only those with positive cytology and/or colposcopy screening results received 
biopsy. Because not all patients received biopsy, the authors adjusted prevalence 
estimates using the prevalence of cancer in the biopsy group and applied an 
incident rate to negative women based on an eight month follow up period. While 
internal validity is good, it is not known whether these results would apply to 
populations in low resource settings as this study took place in private gynecology 
practices in Germany. 
A study done by Wu et al (2005) in China compared the efficacy of colposcopy, 
HPV DNA testing, liquid based cytology, and visual inspection with acetic acid in 
identifYing any squamous intraepitheliallesions and worse lesions. The study 
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population included 450 women age 20-74 years of age without history of 
cervical biopsy, all of whom received VIA and HPV testing. Only 273 underwent 
all four screening procedures "because of the good results of visual inspection"19• 
VIA had the lowest sensitivity (38.9%) and specificity (68.5%) while colposcopy 
was the second lowest with a sensitivity of55.6% and specificity of79.4%. 
These values are low for a screening test. Liquid based cytology had a higher 
sensitivity than both methods with 77.2% sensitivity and 98.63% specificity. This 
study was of fair quality because it was not randomized (patients chose which 
methods they did not want to receive), blinding was not described in the article 
and no reference to the colposcopist' s experience was given. Furthermore they 
did not discuss whether the results were significant or not, and the meanings 
behind this. They concluded that because of the high levels of false negative tests 
from VIA and colposcopy for patients with low grade dysplasia, neither should be 
used in the early detection of cervical dysplasia19• 
Massad and Collins (2003) evaluated the correlation of colposcopic impression 
with biopsy results in a study of2ll2 women with both colposcopy and biopsy 
results 35• They found that the association between colposcopy results and biopsy 
pathology was significant (p<O.OOI), although the kappa statistic suggested a 
weak correlation of 0.2 between results. They found that there was exact 
agreement in the grade of cytological lesion in only 37% of cases, although this 
increased to 75% when the colposcopy result lay within one histological grade of 
the biopsy result. The sensitivity of colposcopy in detecting lesions worse than 
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CIN II was 56% and specificity for the detection of atypia or worse was 52%. 
They concluded that while colposcopy may assist in estimating the grade of 
cervical lesions, it is not precise and increases risk of over diagnosis and over-
treatment of patients when used alone in screening. The Massad and Collins 
study was of good quality overall. This study was not randomized as performing 
biopsy without indication would be unethical. The patients were referred after 
having abnormal Pap smears, and thus were at higher risk than an average 
individual and the residents performing the examination were not blinded to this 
information. Measurement bias may have been introduced as the physicians 
already had a high index of suspicion. Inter-observer variability may be at issue 
as different residents performed colposcopy. This study is generalizable to urban 
populations with a high proportion of women of African American and Hispanic 
descent and an average age of 33 years. 
Finally, Cantor et al (1998) did a cost effectiveness study comparing new 
screening methods (speculoscopy) to colposcopy in traditional screening methods 
and see and treat methods. There has not been a cost effective analysis 
comparing other see and treat methods to see and treat colposcopy. Cantor eta! 
used data from nine studies and their clinic to generate probabilities of true 
positives and negatives and false positives and negatives using weighted average 
of prevalence from each referral population (all based in high resource nations)33• 
Colposcopy had a high sensitivity at 94% and low specificity at 48% in 
distinguishing between presence versus absence of cervical dysplasia33• When 
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distinguishing between high grade versus low grade dysplasia, the sensitivity 
dropped to 79% and specificity to 76% however. In order to approximate cost, 
Cantor et al used charge data from one US based hospital system and compared it 
to cost per high grade lesion detected. They found that colposcopic directed 
biopsy was most expensive (this requires 2-3 visits from the patient) at $311,808 
to detect 45.78 cases. When a see and treat protocol was used 46.05 cases were 
found per $285,133. Colposcopy dominated spectroscopy in cases found per cost 
in both screening protocols. This analysis was based on US health system costs 
and did not incorporate a societal perspective of benefits and costs (such as life 
years gained). This study further supports the ability of colposcopy to identifY 
presence versus absence of cervical dysplasia, but inability to distinguish between 
high and low grade dysplasia in developed nations. Cost effectiveness must also 
be determined in low resource countries prior to discarding this method. 
Two methods have been shown to decrease prevalence of dysplasia in a see and 
treat protocol in low resource settings, yet the large ranges in colposcopic 
sensitivity and specificity found in other studies introduces doubt as to the 
accuracy of this method. Prior studies examining accuracy have varied widely for 
many reasons including differences in the characteristics of study populations, 
variability of colposcopy skills, presence in high resource settings and more This 
study will characterize the accuracy of colposcopy in Haiti, and these results will 
determine whether this method is adequate for a see and treat protocol using 
colposcopy as the primary method .. 
Methods 
Study Questions and Hypotheses 
Reports on screening and diagnostic accuracy of screening colposcopy have 
varied significantly in the literature. Medical records data from the Leogane, 
Haiti Cervix Clinic were used to characterize the accuracy of these methods at 
that specific clinical site through the examination of two questions: 
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Analysis 1: How accurately does the US gold standard screening method, 
Pap smear, identify mild dysplasia (CINI) or worse lesions as compared to 
gold standard diagnostic testing with biopsy? 
Analysis 2: How accurately does screening colposcopy identifY mild 
dysplasia or worse lesions as compared to diagnostic biopsy? 
Ho: Colposcopy will perform with less sensitivity and specificity than 
Pap smears when comparing each to the gold standard, biopsy. 
Alternative hypothesis: Colposcopy will perform the same as Pap smear in 
sensitivity and specificity analysis when compared to the gold standard, 
biopsy. 
Study Populations 
Recruitment to the Leogane clinic occurred via word of mouth from patients who 
visited the clinic, and often included women with various vaginal symptoms 
seeking acute care. This stndy includes three different accuracy analyses and 
therefore three final stndy groups were created based on which clinical 
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evaluations were received by the source population. Inclusion into at least one of 
the two study populations required that a patient have a minimum of two clinical 
procedures, including Pap smear, colposcopy and/or cervical biopsy. See Figure 
1 for a visual depiction of the study populations. 
Clinical Protocol and Data Collection 
The clinic nurse gathered demographic data via interview with each new patient. 
The physician visually examined the vulva, vagina and cervix of each patient. The 
physician performed Pap smear and colposcopy on each patient and biopsy if 
indicated. Two different protocols were instituted over time, the first of which 
took place from 01/2000 through 08/2005. During this phase, the physician 
would not perform cervical screening tests until after the administration of 
treatment to all women that had vaginal or cervical infections. Loss to follow up 
was high and it is believed that patients did not return to the clinic if their 
symptoms had resolved, or other barriers intervened such as finances. From 
08/05 untill2/05 the predominant strategy was to perform screening or diagnostic 
evaluation with Pap smear at the initial visit regardless of whether or not there 
was cervical or vaginal infection. All of these patients were required to return to 
the clinic in order to receive and pay for the Pap results and also to receive 
colposcopy. 
After the initial interview and physical examination, the women underwent 
different combinations of the three procedures: Pap smear, colposcopy, and 
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cervical biopsy, depending on the predominant protocol and patient behaviors. 
Pap smear was performed by rotating a wooden stick at the opening of the 
cervical os and smeared the sample on a glass slide. Thereafter the physician 
rotated a cytobrush in the internal cervical os smeared this sample on a clean 
section of the glass slide. The slide was then sprayed with a fixer. The physician 
was blinded from Pap results prior to colposcopy as the cytology lab withheld Pap 
results in a sealed envelope. 
The physician performed colposcopy after applying 3% acetic acid to the cervix 
and made a colposcopic diagnosis and recorded the results. He opened the 
envelope with Pap smear results for women that returned to the clinic from a 
previous visit to ensure that a lesion was not missed on a normal appearing cervix. 
Cervical biopsy and/or endocervical curettage was performed if the physician 
identified dysplastic-appearing lesions and cervical samples were placed in 1 0% 
neutral buffered formalyn. 
In order to receive cryotherapy as treatment for cervical dysplasia the physician 
required patierits to return to the clinic for the biopsy results. The nurse recorded 
all data obtained into a computer database in Filemaker Pro. The clinical practice 
in which this medical records data was gathered rarely practices a screen and treat 
approach. Patients who were certain that they could not return were offered 
cryotherapy prior to the return of biopsy results. The data is being analyzed to 
evaluate the potential effectiveness of a single day screen and treat approach. 
23 
A total of 2106 women attended the clinic between January of 2001 and 
December of2005 and were ages 19-80 from Leogane and surrounding regions. 
Of the 2106 women, 82 women had no record of cervical screening and they were 
excluded leaving a total of2024 women with at least one documented evaluation 
(See Group A, Figure 1). From these 2024 women, a total of23 women did not 
have a Pap smear as part of their evaluation. This meant that 23 women had 
results available only from colposcopy and biopsy (See Group B, Figure 1 ). Two 
reasons for missing results include failure of patients to take slides or biopsy 
results to the laboratory, failure of patients to return to the clinic for lab results, 
and finally the clinic ran out of supplies for certain tests at different times. 
A total of200I women underwent a Pap smear as part of their evaluation. Of 
these, 158 women had a Pap smear as part of the one day screening protocol and 
20 were excluded because they had only a Pap smear and no further evaluation. 
A total of 127 had both Pap smear and colposcopy while II (Group C) women 
had Pap smear, colposcopy and biopsy during the second clinical screening 
protocol. 
From the 2001 women that had Pap smears, 1843 did not undergo the one day 
screening protocol and were asked to return. A total of 689 women were 
excluded from this analysis because they did not return after the Pap smear results 
24 
and colposcopy. This means that 34% of the women that were asked to return to 
receive Pap smear results did not return for their second visit. 
After initial evaluation with Pap smear, 1,154 returned for further evaluation. The 
remaining women were included in at least one of the two analyses performed in 
this study. A total of 187 women had Pap smear, colposcopy and cervical biopsy, 
allowing for a comparison of results from each of those tests (Group D, Figure 1 ), 
while 967 women had Pap smear and colposcopy ouly. 
The fmal study group for the first analysis included 198 women and will be used 
to calculate diagnostic sensitivity and specificity of Pap smear against biopsy, 
(diagnostic gold standard for cervical cancer). The second analysis had a total of 
221 women with colposcopy and biopsy results, for which and sensitivity and 
specificity of colposcopy will be assessed by comparing it to biopsy as the gold 
standard. A total ofl,315 women had at least two evaluations performed. See 
Table 2 to view the final study populations for each analysis. 
Variables: 
Pap Smear Results 
Cytological results of Pap smears obtained from the clinic's laboratory were 
graded independently for inflammation and cellular atypia. Cellular atypia was 
graded as normal, mild moderate or severe inflammation, mild dysplasia (CIN I), 
moderate dysplasia (CINII), severe dysplasia (CIN III) or carcinoma All patients 
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with any level of dysplasia or carcinoma were considered to have a positive Pap 
test. In 2000, Pap specimens were sent to a Pittsburgh laboratory for validation. 
The lab performed independent cytological evaluation and found that results 
obtained by the Leogane lab were comparable (data not available)*. 
Colposcopy Results 
The diagnostic result nsed for see and treat colposcopy is a "colposcopic 
impression'', or preliminary diagnosis that a Haitian physician records after 
viewing the cervix through a colposcope. This includes normal, infection, 
inflammation, mild dysplasia, moderate dysplasia, indeterminate grade dysplasia, 
and cancer. For this study, dysplasia or cancer constitutes a positive result while 
infection, inflammation and normal constitute a negative result. 
Biopsy Results 
The specimens for biopsy results were taken from the endocervical canal, the 
outer cervix or both. The highest grade lesion seen on biopsy was recorded as the 
final diagnosis. Results included normal cervix, chronic cervicitis, HPV change, 
mild dysplasia, moderate dysplasia, severe dysplasia, microinvasive cancer and 
carcinoma. A positive result includes any level of dysplasia, or any stage of 
carcinoma Pathology services were provided by the Hopital St. Croix of 
' Validity of Pap smear verified through personal communication with Dr. David Walmer, 
Chairman ofFHM on 05/15/06 and 06/20/06. He reports that this evaluation was performed at 
Mercy Hospital of Pittsburgh, PA by Dr. Rosemary Edwards. 
26 
Leogane and were also validatedt. for accuracy by an independent laboratory. 
For categorization of other variables, see Table 3. 
Patient Age 
A total of 1309 women reported their age at the time of their initial evaluation. 
Women were divided into four age groups: 19-30,31-40,41-50 and 51-80. The 
cut-offs for these groups was based on the recommendations of the World Health 
Organization for cervical cancer screening in areas where resources are limited36• 
The main cervical cancer prevention documents state that screening is not 
recommended before age 30 as its prevalence is rare in this group ofwomen36• 
Current research indicates that women should receive at least one screening 
examination during the third, fourth and fifth decades of life36• Other co variates 
assessed in the descriptive analyses include age of first coitns, number oflifetime 
sex partners, marital statns, gravidity, current irregnlar menstrual cycle, presence 
of postcoital bleeding. These data were obtained from the medical records. Refer 
to Table 3 for specific categories. 
Se and Sp Analysis 
In order to evaluate screening and diagnostic accuracy of Pap smears, and see and 
treat colposcopy in this low resource setting, I performed two analyses. These 
analyses address the diagnostic accuracy as sensitivity and specificity by 
comparing each screening test to cervical biopsy as the diagnostic gold standard. 
t Validity of Pap smear verified through personal conununication with Dr. David Wahner, 
Chairman ofFHM on 05/15/06 and 06/20/06. He reports that this evaluation was performed at 
Mercy Hospital of Pittsburgh, PA by Dr. Rosemary Edwards. 
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Both analyses involved calculation of sensitivity, specificity, positive predictive 
values and negative predictive values. The data was stripped of all identifiers and 
the Institutional Review Boards ofUNC-Chapel Hill and Duke University 
determined that the study was exempt from IRB revieW'. 
I used Stata version 8.0 for all descriptive statistics and to create a bivariate two 
by two table for each analysis. The bivariate tables describe the number of 
patients that were positive or negative for disease and the test's ability to correctly 
identify this in each analysis. Groups were labeled as a, b, c, d and corresponded 
to (See Tables 4A and 4B to view organization of bivariate tables): 
a~ the numbers of true positives (diseased subjects with correct positive test results) 
b~ false negatives (disease, but negative test) 
c~ false positives (no disease, bnt positive test) 
d~ true negatives (no disease, negative test) 
Sensitivity, specificity, positive predictive value, and negative predictive values 
were also calculated by Stata. Sensitivity was calculated as the proportion of 
women for whom the test correctly identified as positive for disease divided by 
the number of women that were correctly identified as positive plus those that 
tested negative but truly had the disease [a/(a+b)]. Specificity was determined as 
the proportion of women that were correctly identified as negative for disease 
divided by the number of women that were truly negative plus those that were 
1 University of Chapel Hill study #06-0 172 
Duke University approval given by Dr. Joho Falleta on 01/31/06 
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falsely positive for the test d/( c+d). Statistical significance was calculated as 95% 
confidence intervals by Stata using the Wilson score method. 
Positive predictive value (PPV) is the proportion oftest positives that were correct 
a/( a+c) while PPN was the proportion to test negatives that was correct d/(b+d). 
These calculations were calculated for each screening test as follows: 
Sensitivity x Prevalence 
PPV == -------------------------------------------------------------
Sensitivity x Prevalence+ (!-Sensitivity) x (!-Prevalence) 
Specificity x (!-Prevalence) 
PPN == -------------------------------------------------------------
Specificity x (!-Prevalence)+ (!-Specificity) x Prevalence) 
The prevalence of cervical cancer was calculated by Stata and based on the 
presence of carcinoma from biopsy results in this study population. 
Analysis One 
The first analysis addressed the issue of whether Pap smears can adequately 
diagnose cervical intraepithelial neoplasia grade I (CIN I) or worse lesions 
compared to biopsy from the 150 women that had both Pap smear and cervical 
biopsy. I performed this analysis by calculating the sensitivity and specificity of 
Pap smears against the diagnostic gold standard of cervical biopsy. Sensitivity, 
specificity, PPV and PPN with 95% confidence intervals were calculated by Stata 
using biopsy results to verify the true presence or absence of disease. 
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Analysis Two 
The second analysis evaluates the ability of screening colposcopy to identifY CIN 
I or worse lesions from the 145 women with results for both of these procedures. 
For this analysis, I compared colposcopy results to the results of the diagnostic 
gold standard, cervical biopsy. Sensitivity, specificity, PPV and PPN were 
calculated as described above with 95% confidence intervals for each of these 
calculations. 
Results 
Characteristics of the Study Populations 
A total of 2,094 individual women (See Group A, Figure 1) had at least one 
analysis performed and data recorded, although there was missing data for certain 
variables in the descriptive statistics section and this is noted for each variable in 
Table 3. Missing data was reported for each variable and not included in the 
calculation of percentages. The average age for this entire population was 42.5 
years (standard deviation!SD= 1 0.5) ranging from 19 through 80 years. The 
predominant age categories for the group A population women was age 31-40 
with 32% (n=422) of the population, and the 41-50 age group with 32% (n=419) 
of the population. 
The majority of women in all populations, 59.8% (n=787), reported only one 
lifetime sexual partner and a very small proportion, 2.4% (n=31 ), of the combined 
population reported having more than 5 lifetime sex partners. This was similar to 
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the populations for each of the analyses (Table 3). Most women in all population 
groupings reported either living with their partner or being married, while fewer 
women were part of the single and/or divorced category. Few women (9.7%, 
n= 127) from group A study reported that they had never been pregnant. Analysis 
I (groups C+D) and analysis 2 (groups B+C+D) had even fewer women reporting 
a gravidity of zero at 4.5% (n=9) and 4.1% (n=9) respectively. Most women 
reported a gravidity of 1-4. Refer to Table 3 for additional descriptive variables. 
Prevalence of Cancer by Diagnostic Test 
A total of24.4% (n=54) women from analysis 2 (groups B+C+D) had gross 
cancer that only required visual inspection for diagnosis. This contrasts with the 
48% (n= 1 06) of women from the same group with dysplasia or cancer on biopsy, 
the gold standard. I included two different combinations of categories for Pap 
smear results. The frrst categorization included groupings for normal, abnormal 
but not dysplasia, dysplasia, and cancer. For these results, very few women had 
normal results on Pap in any of the groups, with the highest proportion at 2.0% 
for group A. A very large proportion of women had abnormal findings on Pap 
smear but not dysplasia (meaning inflammation/ infection) for all analysis groups, 
including 93.2% (1207) of the women from group A. 
A total of 13.5% (n=l77) women had cancer or dysplasia on colposcopy for group 
A. Analysis 1 and 2 had high prevalence of cancer or dysplasia with colposcopy 
ranging from 66.7% (n=l32) to 70.1% (n=155). Finally, the results for biopsy 
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were only relevant for the populations that had this evaluation performed. 
Analysis 1 showed that 41.9% (n=83) of the women had dysplasia or cancer while 
analysis 2 had a percentage of 48.0% (n=1 06) with dysplasia or cancer on biopsy 
(Table 3). 
Sensitivity and Specificity of Pap Smear vs. Biopsy 
Analysis 1 entailed the comparison of Pap smear results to biopsy results from 
groups C+D (See Figure 1 ). The bivariate analyses with positive test results for 
the diagnostic test and test variables are included in Table 4A. The sensitivity of 
Pap smear compared to biopsy was 68.7% (CI 57.6-78.4) and specificity for Pap 
smear compared to biopsy was 96.5% (CI 91.0-99.0. Of those screened using 
Pap, 93.4% (CI 84.0-98.0) truly had disease whereas 81.0% (CI 73.0-87.0) 
correctly screened negative for disease with Pap. 
Sensitivity and Specificity of Colposcopy vs. Biopsy 
Analysis 2 included groups B+C+D in the study population and colposcopy and 
biopsy results were compared. The bivariate table with the number of test 
positives and negatives is available in Table 4B. Colposcopy was able to identify 
more cases than Pap with a sensitivity of96.2% (CI 91.0-99.0) but colposcopy 
had less ability to rule out cases with a specificity of 53.9% (CI 44.0-63.0). 
Colposcopy correctly identified 65.8% (CI 58.0-73.0) women with disease while 
the negative predictive value was 81.0% (73.0-87.0) (Table 5). 
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Discussion 
The US and Europe have significantly reduced the morbidity and mortality of 
cervical cancer programs that use serial Pap smear, colposcopy and biopsy as the 
major tools of screening in their respective environments11• 34• These methods 
have not been widely available in low resource settings and clinicians have 
encountered other difficulties in their use, such as the need for multiple visits 
from patients for screening, diagnostics and treating women. See and treat 
methods have gained popularity and validity in the past decade, although the tools 
for screening may be lacking in accuracy. This study focused on the determining 
the accuracy of screening colposcopy, as this method may be applied in a screen 
and treat protocol in a low resource program in Haiti. This method would require 
fewer laboratory services, and less frequent follow up appointments from women 
that experience difficulty returning to the clinic. For example, 34% of the women 
attending the clinic that had an initial Pap smear did not return for their results or 
further evaluation. 
Summary of Key Findings 
In this study, the prevalence of disease was not statistically different for the Pap 
smear +biopsy population than the colposcopy+ biopsy population. The results 
for sensitivity of Pap were low while specificity was good. Colposcopy was able 
to identizy more cases than Pap, with a significantly higher sensitivity, although 
colposcopy had a significantly lower specificity. 
33 
The positive predictive value (PPV) of Pap was high with fairly narrow 
confidence intervals. The PPV of colposcopy demonstrated a fair percentage of 
correctly identified patients with dysplasia or cancer at 65.8% (CI 0.58-0.73), 
which is significantly different from the higher PPV for Pap smear (93.4% (0.84-
0.98). The negative predictive value (PPN) for Pap and colposcopy was good and 
the results did not significantly differ, as the confidence intervals overlapped. 
Interpretation of Findings 
We expected that colposcopy would perform with less sensitivity and specificity 
than Pap smear when comparing each to the gold standard, biopsy. This was 
incorrect in the case of sensitivity, however, as colposcopy was able to identifY 
positive cases with much higher capability than Pap smear. Our original 
hypotheses also predicted that colposcopy could not rule out disease as well as 
Pap smear, and this proved to be true. In addition, Pap smear was able to 
distinguish positive cases that actually had disease significantly better than 
colposcopy could. This suggests that Pap smear misses more disease while 
colposcopy is better in identifYing cases. Both tests were able to identifY women 
that were truly negative for disease at similar levels. 
Current knowledge on the accuracy of screening colposcopy has shown mixed 
results depending on multiple factors determined by the setting in which studies 
are carried out. The Schneider et al (2000) study was performed in Germany, 
where screening colposcopy is used in standard practice as a component of 
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cervical evaluation and screening34• They found that screening colposcopy had a 
very low sensitivity at 13.2(95% CI 7.3-19.6) for moderate dysplasia or worse 
lesions. They also found that the specificity of screening colposcopy was good at 
99.2% (95% CI 98.9-99.4). The sensitivity for cytology was still poor for Pap 
smear, and not significantly higher at 18.4 (11.6-25.7) and there was no 
significant difference in Pap smear specificity, which was 99.0% (98.7-99.3). 
The results of my study demonstrated the opposite effect from the Schneider 
study, in which sensitivity for colposcopy was significantly higher than Pap at 
96.5% (CI 0.91-0.99) while the specificity was fair, although significantly lower 
than Pap at 53.9% (0.44-0.63). The PPV for colposcopy in the Schneider study 
was poor at 28.8% (95% CI 17.0-41.5) and the PPN was good at 97.9 (CI 97.5-
98.3). This study found that the PPV for colposcopy was significantly higher than 
colposcopy in Schneider et al's study, where the PPV was 65.9% (CI 0.58-0.73) 
and a PPN of93.7% (0.85-0.98). Overall, the results for my study reveal a better 
sensitivity and positive predictive value for colposcopy, worse specificity, while 
the negative predictive value was not significantly different than that found in the 
Schneider study. Also, my results for Pap smear sensitivity were a minimum of 
3.18 times higher than found in that study, while specificity for Pap was high and 
not significantly different. 
Various issues may contribute to the differences found between these two studies. 
The populations screened in each of these studies demonstrate different 
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background characteristics such as age. The Schneider et al study reported a 
mediau age of35, whereas the meau age for my study was 44.5 (SD 1 0.5). In 
addition, the prevalence of CIN II, CIN III aud caucer on biopsy in the Germau 
study population was much lower at 2.4%. The difference in age may have 
affected the prevalence of disease as the highest incidence of cervical caucer is 
found between the ages of 30 aud 6011• 36• The prevalence of dysplasia or caucer 
on biopsy for the larger study population (aualysis 2) in my study also included 
CIN I aud was 48.0%, aud therefore including auother level of dysplasia would 
also presumably increase prevalence in my study. Despite the inclusion of CIN I 
patients in my study, the huge difference in prevalence suggests that dysplasia aud 
caucers are more prevalent in the Haitiau population aud this may contribute to 
the higher sensitivity of colposcopy in this study. Finally, the study size of the 
Schneider study included 5,455 women aud therefore the results are likely a 
closer estimation to the truth, whereas my study populations around 200 women 
may have allowed for sufficient raudom error to make the results inaccurate. 
The study done by Wu et a! (2005) demonstrated a sensitivity of colposcopy was 
55.6%, which is 35.4 percentage points less thau the lowest end of the confidence 
interval sensitivity I calculated in my study. The specificity for colposcopy in the 
Wu study was significautly higher thau what I found in my study at 79.45%. The 
Youden index score for colposcopy was 0.35, which suggests that this screening 
method was not ideal in the setting in which their study was carried out. ThinPrep 
cytology was more accurate thau conventional Pap with a 72.2% sensitivity, a 
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98.6% specificity and Youden index of0.7, which was higher than that for 
colposcopy19• Overall, their cytology test did not perform significantly different 
from Pap smear sensitivity and specificity in my study. The sensitivity of 
colposcopy in my study was significantly higher than their results while 
specificity between the studies was not significantly different. Colposcopy use in 
Haiti is able to identifY more cases than the Wu study, yet the ability to identifY 
patients without disease was similar between studies. Thus colposcopy as used in 
Haiti was an overall better screening test than in the Wu et a!. study. 
One disadvantage to comparing the results of the Wu et a! study, is the fact that 
they did not calculate confidence intervals for their diagnostic accuracy values. In 
this sense it is impossible to truly determine whether the range of confidence 
intervals were significantly different from their study, although it seems as though 
the differences are large enough that intervals would not overlap in most cases. 
Both studies had fairly small populations as well and thus may be subject to 
random error more than large study populations. 
The results of my study fall into the range of the results found in the meta-
analysis for colposcopy performed by Mitchel et ae0• They reported that the 
sensitivity of colposcopy ranged from 64 to 99% and the specificity from 30 to 
93%. My sensitivity result was at the higher end of their range, and my 
specificity was at the lower end of the range for specificity of colposcopy values 
from that meta-analysis. This supports that the accuracy colposcopy in Haiti falls 
into the known range of results. Additionally, Mitchell's study included studies 
of high prevalence as only women referred for colposcopy because of abnormal 
Pap results and therefore prevalence of disease would be higher in their 
population. The study populations in those studies are similar to my study 
population in having a high prevalence of dysplasia and! or cancer. 
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The results of the Massad and Collins study may reflect underlying causes for the 
fair specificity found in my study5• They reported that colposcopy had poor 
capability to predict the exact result of biopsy, however results within one 
histologic grade agreed in 75% of cases. The sensitivity for finding CIN II/III 
lesions for their study was 56% while specificity to rule out any atypia or worse 
lesions was 52%. The sensitivity for my study was significantly higher, while 
specificity was not significantly different than their study. This suggests that 
screening colposcopy as used in Haiti is a better screening tool than in urban areas 
in the US. This may be attributed to the higher prevalence of disease in Haiti. 
The sensitivity in the Massad and Collins study may be lower because they did 
not include low-grade dysplasia. Their study population had a lower mean age of 
33.5 years which is a decade younger than the mean age for my populations. 
Although they state that their population largely included a higher risk group with 
African America and Hispanic women, the prevalence of cervical cancer and 
dysplasia even in these populations is not as high as it was in the Haitian 
population. 
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This analysis demonstrates that colposcopy is carried out with high levels of 
sensitivity and specificity in Haiti. In a population with a high incidence of 
cervical cancer and dysplasia it is important to use a screening method that is able 
to identifY a high proportion of disease, while also retaining ability to rule out 
disease. The use of colposcopy in Haiti does not have a high level of specificity, 
which means that incorporation into a one day screen and treat protocol would 
lead to unnecessary treatment for a proportion of women. This issue must be 
carefully weighed and evaluated as disease prevalence and mortality from cervical 
cancer in Haiti is high. A treatment strategy that minimizes morbidity in patients 
without disease may be a small cost with the large benefit of saving a large 
proportion of lives. The high loss to follow up (34%) and the high prevalence of 
dysplasia in the Haitian population speak to the need for a screen and treat 
method. The low sensitivity of Pap smear in this population signals the need for a 
test that identifies cases more accurately. Colposcopy is a good candidate that 
fulfils these requirements; however one must consider the morbidity associated 
with any treatment method incorporated into a one day protocol. Cryotherapy is a 
viable option over conization or Loop Electrosurgical Excision Procedure (LEEP) 
as several studies have demonstrated little effect on pregnancy outcomes in 
women that have undergone this treatment37• 38• One issue with this treatment 
modality lies in the high percentage of women with inflammation on Pap smear in 
this Haitian population (93.2%). While one study performed in Greece 
demonstrated that 86% of women with chronic cervicitis treated for dysplasia 
with cryotherapy made full recoveries, enviromnental factors such as poverty may 
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influence recovery differently in the Haitian population39• This suggests that 
colposcopy may be used in conjunction with a screening method that has high 
specificity for cervical dysplasia, thus preventing over treatment and the risks that 
may arise therein. 
Limitations of This Study 
One limitation of this study lies in the study design. Because this study was based 
on medical records from routine clinical care and not a designed scientific study, 
randomization to various methods of cervical evaluation was not possible, or 
ethical. The likely effect of this was probably increased selection of the women 
that received biopsies because of a higher index of suspicion after abnormal Pap 
and/or colposcopy results. For example women with more obvious clinical signs 
may have been more likely to receive biopsy than those with mild dysplasia. This 
would increase the prevalence of disease and also increase the value for 
sensitivity. Also, because of the study design, I can only hypothesize that this 
screening tool would work in a see and treat approach. Basic accuracy data on 
sensitivity and specificity does not necessarily translate into the effectiveness of a 
screening program to decrease mortality from cervical cancer. 
A second limitation was that this study only delineates between all levels of 
dysplasia versus normal/abnormal. Because mild dysplasia (CIN I) often 
resolves, other studies include only moderate dysplasia (CIN II) or worse lesions 
as a "positive" test result. Thus, this study would have a higher prevalence of 
disease and lower threshold for diagnosis. If these accuracy results were to be 
used in a see and treat protocol, there is a risk of over-treating the population. 
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A third limitation is that bias may have been introduced in several areas. As 
noted previously, selection of the biopsy populations may have occurred due to a 
combination of interacting factors. These factors may have lead to selection bias 
in terms of which women from the larger Haitian population attended the clinic. 
Because of the large number of abnormal Pap results, these patients may have had 
infection or symptoms that lead them to the only gynecologist in the area As 
such, these patients may have different risk factors from other women in low 
resource areas. 
A fourth limitation is that all demographic information was given by patient 
report and the questions asked by the nurse are not standardized or validated. 
Upon visiting the clinic I discovered that there may be more than one patient in 
the room during a patient's clinic appointment and it is possible that patients 
answer sensitive questions based on the expected or moral answers. This may be 
the case with questions regarding the number of lifetime sexual partners, for 
instance. 
Finally, there may be an issue with the nurse's understanding of some of the 
questions that she asked and this was apparent in the gravidity and parity 
statistics. For example, in the combined study population 53.1% of the women 
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reported 1-4 pregnancies whereas 60.4% reported that they had 1-4 live births. It 
is impossible to have more live births than pregnancies unless there are problems 
with the question or its comprehension. This highlights the importance and 
difficulty of working across languages but signals an important issue that can now 
be addressed in future data collection. 
Strengths of This Study 
There were, however several strength in this study. This study was important to 
provide feedback on the current state of cervical cancer screening in Haiti. While 
it does not establish a screening method that is better than Pap overall, it does at 
least establish a role for colposcopy in this clinic. This will provide a foundation 
from which future development of methods may be developed and improved 
upon. For instance, colposcopy was more sensitive in identll)ring cases, although 
Pap was able to rule out disease with more accuracy. One reason that Pap smear 
may have such a low sensitivity in this setting may lie in the fact that there was a 
large population of women that had abnormal results due to inflanunation or 
infection. Haitian physicians have reported the difficulty of using Pap smear 
previously as many results are clouded by obscuring inflanunation. This was 
evident in the study population characteristics presented in Table 3, where the Pap 
smear and biopsy group (analysis I) demonstrated that 68.2% had abnormal 
results (not dysplasia or cancer) on Pap smear. Alternatively, a problem with 
correct cytological diagnostics may be the cause of this problem yet the fact that 
these services exist at all is a benefit available in very few areas in Haiti. This 
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problem further supports the need for a screening program that can identifY cases 
better than Pap smear in this population of women. 
Another strength of this study was the fact that that the clinical protocol and data 
collection for this study were carried out with good standards in a low resource 
setting. The use of File Maker Pro to record results was likely to ensure that the 
demographic data as well as test results were correct for each patient in this 
dataset. Furthermore, because these were the medical records used daily by the 
Haitian staff, it was in their interest to ensure correct information for good patient 
care. The tools used to evaluate cervical findings were the best available in the 
community in which these methods were carried out, and far above the standard 
of care for the nation. 
A third strength of this study was that measurement bias was limited in at least 
one respect. Inter-observer variation in the evaluation results was controlled as 
the same physician determined all of the colposcopy results, the same cytologist 
diagnosed all Pap smears and the same pathologist determined all biopsy results. 
On the other hand, it is difficult to ensure that results for pathology services were 
valid. Although Pap smear results were reported to be validated by a Pittsburg 
laboratory at a previous date, the fact that the results of that analysis are not 
available also puts the validity of Pap smear results into question. These are the 
tools that are available in this setting, however, and their use and evaluation is 
important in any studies seeking to analyze screening methods in Leogane. 
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The population included in the study demonstrated certain characteristics that 
increase the risk of cervical cancer. The mean age of the population was typical 
of that worldwide at 44.5 (standard deviation 10.5) as it is the third, fourth, and 
fifth decades in which cervical cancer incidence is highest36• The majority of 
women reported only one lifetime sexual partner, for instance 59.8% 
(n=787 /1315) of the combined study population reported this, while the majority 
of the remainder of the populations reported having 2-4 lifetime sex partners. 
Despite this, the prevalence of dysplasia or cancer in this population appears to be 
high, for instance the prevalence in the Pap smear and biopsy group (analysis 1) 
was 4.8% (n=62). This suggests that other factors may contribute to the 
development of cervical cancer in this population and future research may 
investigate the association of population specific risk factors with development of 
cervical cancer. More research is required to determine what these risk factors are 
and how they may be different from other populations in low resource settings. 
Public Health Implications 
This study is important in the consideration of cervical cancer screening methods 
in low resource nations. Because of challenges presented to both clinicians and 
patients in these settings, a method that decreases the number of follow-up 
appointments while also sufficiently decreasing the number of cases is desired. 
For this reason many researchers have been working toward the development of 
see and treat methods internationally. Using colposcopy in Haiti seemed to be 
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appropriate as a local program had acquired the clinical knowledge and skill as 
well as resources to carry this method out along with the use of routine screening 
and diagnostic procedures. Because it is a relatively rapid screening process, and 
results are immediately available, it would allow for treatment of cervical lesions 
on the same day a patient attended her frrst visit. While this test demonstrated an 
excellent ability to identifY cases, its low specificity would not rule disease out in 
many women that did not have dysplasia. This means that this test has the 
potential to decrease disease in this population however the costs of over 
treatment remain to be determined. Future study should incorporate a test with 
high specificity such as Pap smear or HPV DNA testing to prevent treatment in 
patients without disease. Simultaneously, morbidities such as continued ~ ~--
inflammation and/or infection should be recorded from women with true disease 
for whom treatment is indicated. 
In this study I also characterized the accuracy of the Pap smear as used in 
Leogane and established a baseline of the accuracy this screening method 
provides. At present, the sensitivity is fair and the specificity was excellent. The 
overall results found herein emphasize that other methods need to be explored to 
address the issue of prevention of cervical cancer in this and other low-resource 
settings as disease is not reliably identified by this screening method. Other 
methods including colposcopy, HPV DNA testing or the use of Visual Inspection 
with Acetic acid appear to have adequate accuracy while also addressing issues of 
cost and difficulty of follow-up. 
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Conclusions 
The use of colposcopy over Pap smear for cervical screening in Leogane, Haiti 
remains a viable option because of many characteristics of the test that would 
allow for easy treatment. The accuracy of the test itself as used in the Cervix 
Clinic was significantly higher than Pap smear yet specificity was lower than Pap 
at 53.9% (0.44-0.63). These findings fit within the ranges of results of most other 
studies performed in high-resource settings with this screening method. At the 
same time, Pap smear accuracy was not good, although better than results found 
in Germany, Zimbabwe, and other nations with a sensitivity of 68.7% (0.58-0.78) 
and specificity of 96.5% (0.91-0.99). These results demonstrate that the 
worldwide screening gold standard varies by prevalence of disease and does not 
yield good accuracy at sites where resources are limited. Importantly, the 
prevalence of cervical cancer among patients with biopsies in this study ranged 
from 41.9% (n=l98) to 48.0% (n=221), which is extremely high. The prevalence 
of cancers and dysplasia detected when Pap smear is assumed to be the gold 
standard was 4.81% (0.04-0.06) (n=2090), and this prevalence is still high enough 
to merit serious revamping of a cervical screening program. Colposcopy may 
serve in a screening program in two capacities: 1. It may simply aid a physician 
in the estimation of the grade of a cervical lesion in conjunction with another 
screening method because of its poor ability to rule out disease 2. It may be used 
as the primary screening tool in a screen and treat protocol if the benefits in lives 
saved outweighs the costs incurred by the treatment method. 
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Figure 1 Study Population Selection Process 
Cervical Cancer Prevention Program 
Leogane, Haiti 2000-2005 
Attended Cervix 
Clinic n~2t 06 
No evaluation 
recorded n~82 
Groul!A 
Have an Evaluation Recorded 
n~2024 
~ 
Had Pap smear as Part of Evaluation 
N~2001 
I 
Asked to Return for Further Evaluation 
n~ 1843 
Groul! B 
No pap smear 
Had Colpo and Biopsy 
n~23 
Had Same Day Screening and Pap 
smear n~l58 
Did not Retnrn 
Had pap and no further evaluation ~I ~ n~689 
Groul! C Pap Only 
n~(20) Pap + Colposcopy Pap + Biopsy + 
Returned for Further n~J27 
Colposcopy 
n~lt 
Evaluation n~ 1154 
~ -o. 
Grou!!D 
Pap & Colposcopy Pap & Colposcopy 
& Biopsy n~967 
n~t87 
Table 1 Summary of Effectiveness of Screening Methods for Cervical Cancer 
in Low Resource Settings 
Cervical Cancer Prevention Program ofLeogane, Haiti, 200-2005 
Author& Screening Study Type Outcome Measure Results 
Year Method Study population 
n 
Denny eta! VIA RCT High grade cervical -6 months after VIA screen 
2005 n~6555 lesions on biopsy (CIN2) and tx: 2.23% of women 
after screening and with positive VIA had 
See and treat treatment for each CIN2 or higher at 6 months 
effectiveness method and control group -p~0.02 
at 6 months and 12 
months 
HPVDNA -6 months after HPV 
Testing screen and tx: 0.80% HPV 
positive women had CIN2 
or higher at 6 months 
-p<O.OOI 
-For delayed tx group: 
3.55% had CIN2 or higher 
Mitchell et a! Colposcopy Meta-Analysis LSIL orHSIL -Weighted average 
1998 n~5978 sensitivity 96% 
9 studies -Weighted average 
specificity 48% 
Massad& Colposcopy Cross Sectional See results Sensitivity 56% for CIN 
Collins comparative II/III 
n~II2 
Specificity 52% for atypia 
and worse lesions 
Hutchinson et LBC Cross sectional ASCUS -Detected 12.7% ASCUS 
all999 comparative or Sensitivity for HSIL 92.9% 
study HSIL P<O.OOI 
n~8,636 
Pap smear ASCUS Detected 6.7% ASCUS, 
or Sensitivity 77.8% for HSIL 
HSIL -P<O.OOI 
niP !EGO Pap smear Cross sectional Mild Dysplasia or worse Sens: 29.6% (95% CI 25.6-
Cervical comparative lesions -33.8) 
Cancer study 
Project, Spec: 92.3% (90.9-93.6) 
Zimbabwe n~I0,934 
1999 
VIA Mild Dysplasia or worse Sens: 63.5% (95% CI 59.1-
lesions 67.7) 
Spec: 63.7% (95% CI 65.0-
69.6) 
Sankaranaraya VIA ClusterRCT -Screening test positivity Detection: 14.0% 
net al2005 High grade::0.7% (p~0.06 
n~I42 701 for all detection results) 
Study 
Quality 
Excellent 
Good 
Good 
Good 
Fair-good 
Good 
HPVtesting -Detection of high grade Detection: I 0.3% 
lesions 
High grade: 1.0% 
Schneider et a! Colposcopy Cross sectional -CIN 2/3 and cancer Senstivity 13.2 (95% CI 
2000 
Wuet. al 
1005 
comparative 7.3-19.6) 
n~5,455 Specificity 99.2(95% Cl 
98.9-99.4) 
Conventional Sensitivity 18.4 (11.6--25.7) 
cytology 
Specificity 99.0 (98.7-99.3) 
Colposcopy as Cross sectional -Presence of cervical Sens 68% 
screening method comparative dysplasia Spec 56% 
n~273 
VIA n-450 Sens 39% 
Spec 68% 
LBC n-273 Sens 72% 
Spec 99% 
HPVDNA n~450 Sens 89% 
Spec 92% 
VIA: Visual Inspection with Acetic Acid; RCT: Randomized Controlled Trial; LBC~Liquir Based 
Cytology; LSIL: Low Grade Squamous lntraepithelial Neoplasia; HSIL~ High Grade Squamous 
Intraepithelial NeoplasiaCI ~Confidence interval; ASCUS~ Atypical Squamous Cells of Undetermined 
Significance 
Fair-Good 
Good 
Fair 
Table2 Final Study Populations for Three Diagnostic Accuracy Analyses in 
Leogane Haiti 2000-2005 
' Analysis Boxes from Figure l Total Number of Participants 
Analysis # l : C+D 198 
Sensitivity and Specificity of 
Pap Smear compared to 
Cervical Biopsy 
Analysis #2: B+C+D 221 
Sensitivity and Specificity of 
Colposcopy compared to 
Cervical Biopsy 
Table 3: Sociodemographic Characteristics and Risk Factors for Cervical Cancer by 
Study Population Characteristics Reported at Initial Evaluation 
Leogane, Haiti 2000-2005 
Group A Pap+ Biopsy Colposcopy+ Biopsy 
n~2094 Analysis I Analysis 2 
(Groups C+D) (Groups C+D+E) 
n~198 n~221 
Age mean, yrs (SO) 44.5 (10.5) 44.4 (9.2) 45.4 (9.9) 
Missing 6 
Age Group 
<::30 267 (13.2) 13 (6.6) 13 (5.9) 
31-40 648 (32.0) 53 (26.8) 55 (24.9) 
41-50 669 (33.0) 86 (43.4) 95 (44.0) 
>51 440 (21.7) 46 (23.2) 58 (26.2) 
Missing 0 0 0 
Number of Partners in Lifetime 
I 1211(59.8) 107 (54.0) 116 (52.5) 
2-4 760 (37.6) 86 (43.4) 97 (43.9) 
>5 53 (2.4) 5 (2.5) 8 (3.6) 
Missing 0 0 0 
Marital Status 
Single or Divorced 42 (2.1) 5 (2.6) 5 (2.4) 
Living with Partner 961 (47.5) 105 (55.0) 116 (56.3) 
Married 957 (47.3) 81 (42.4) 85 (41.2) 
Unknown (64) (7) (15) 
Age First Coitus< 16 268 (13.2) 30 (15.2) 34 (15.4) 
Missing (80) 
Gravidity 
0 184 (9.1) 9 (4.5) 9 (4.1) 
1-4 1074 (53.1) 94 (47.5) 101 (45.7) 
5-15 764 (37.8) 95 (48.0) Ill (50.2) 
Missing 72 0 0 
Irregular Menses Currently 99 (4.9) 8 (4.0) 8 (3.7) 
Unknown 33 3 5 
Postcoital Bleeding 18 (0.89) 5 (1.6) 9 (4.3) 
missing (38) (5) (9) 
Pap Results in 4 categories 
Nonnal 26 (2.0) 2 (1.0) 2 (1.0) 
Abnormal/not dysplasia 1207(93.2) 135 (68.2) 135 (68.2) 
Dysplasia 30 (2.3) 29 (14.6) 29 (14.6) 
Cancer 32 (2.5) 32 (16.2) 32 (16.2) 
missing 729 0 23 
Frank Cancer with Visual 54 (2.68) 32 (16.6) 54 (24.4) 
Inspection (no equipment) 
Missing 76 
Pap Resuits 
Dysplasia or cancer 62 (4.8) 61(30.8) 61 (30.8) 
missing 24 0 23 
Colposcopy Result 
Dvsplasia or cancer 177 (13.5) 132 (66.7) 155 (70.1) 
missing (71 1) 0 0 
Biopsy Result 
Dysplasia or cancer 83 (41.9) 106 (48.0) 
Table4A: 
Bivariate Table for Diagnostic Accuracy of Pap Smear Compared to Cervical Biopsy 
Leogane Haiti 2000-2005 
' Biopsy Results Pap Smear Results 
Positive Negative total 
Positive* 57 26 83 
Negative 4 111 115 
Total 61 137 198 
.. A positive results means that the test demonstrated the presence of dysplasia or cancer_ 
Table4B: 
Bivariate Table for Diagnostic Accuracy of Colposcopy Compared to Cervical Biopsy 
Leogane Haiti 2000-2005 
' Biopsy Results Colposcopy Results 
Positive Negative Total 
Positive* 102 4 106 
Negative 53 62 115 
Total !55 66 221 
Table 5: Accuracy Results From 2 Diagnostic Accuracy Analyses of the Cervical Cancer 
Prevention Program in Leogane Haiti 2000-2005 
' Prevalence ( CI) Sensitivity (CI) Specificity (CI) PPV (CI) PPN (CI) 
Analysis #I: Pap 
Smear compared to 41.9 %(0.35- 68.7% (0.58-0.78) 96.5% (0.91-0.99) 93.4% (0.84- 81.0% (0.73-0.87) 
Cervical Biopsy 0.49) 0.98) 
Analysis #2: 
Colposcopy 48.0% (0.41- 96.2% (0.91-0.99) 53.9% (0.44-0.63) 65.8% (0.58- 93.9% (0.85-0.98 
compared to Cervical 0.55) 0.73) 
Biopsy 
.. CI- 95% Confidence Intervals PPV- Positive Predictive Value PPN- Negative Predictive Value 
